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Abstract 
Background: Dense fibrotic stroma associated with pancreatic ductal adenocarcinoma 
(PDAC) has been a major obstacle for drug delivery to the tumor bed and may impede 
attempts to slow down PDAC progression and metastasis.  However, current anti-
stromal drugs have not improved tumor response to chemotherapy or patient survival. 
Thus, a better understanding of the molecular mechanisms associated with tumor-
stromal interactions is desperately needed to develop novel anti-stromal therapeutic 
approaches. MicroRNAs (miRNAs) are an abundant class of highly conserved, small 
non-coding RNAs that function as key regulators of eukaryotic gene expression and 
cellular homeostasis.  miR-29 is known to play a paramount role in the fibrotic process of 
several organs by providing crucial functions downstream of pro-fibrotic signaling 
pathways such as TGF-β1 and regulates the expression of extracellular matrix (ECM) 
proteins, a major component in the PDAC stroma.  Upregulation of TGF-β1 is associated 
with PDAC pathogenesis and is known to activate stromal cells.  Furthermore, vascular 
endothelial growth factor (VEGF) that stimulates tumor angiogenesis is a predicted 
target of miR-29.  We hypothesize that miR-29 may be misregulated in TGF-β1 activated 
PDAC stromal cells and lead to excessive accumulation of ECM proteins and VEGF. 
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Restored expression of miR-29 could be therapeutically beneficial to modulate tumor-
stromal interactions. 
Methods: Northern blot or qPCR techniques were used to assess miR-29 levels in vitro 
stromal cells, murine PDAC model, and PDAC patient biopsies, and stromal 
deposition/fibrosis was determined by Sirius red staining. In murine and human PDAC 
samples, stromal specific miR-29 expression was determined via in situ hybridization by 
co-staining pancreatic tissues with glial fibrillary acidic protein a marker for stromal cells 
and miR-29. miR-29 functional studies were conducted by transfection of stroma cells 
with synthetic miR-29 mimics and locked nucleic acid, a miR-29 inhibitor, and ECM 
protein/VEGF expression was analyzed by western blot analysis. The effect of miR-29 
overexpression in stromal cells on cancer colony growth was evaluated by direct co-
culture of stromal cells ectopically expressing miR-29 with pancreatic cancer cells, and 
subsequently, cancer colony number and stromal accumulation was determined by 
crystal violet and sirius red stains respectively. 
Results: In both in vitro and in vivo models as well as PDAC patient biopsies, we 
observed loss of miR-29 is a common phenomenon of activated stromal cells, and is 
associated with a significant increase in ECM and VEGF accumulation. Restored 
expression of miR-29 in stromal cells reduced the deposition of matrix proteins, VEGF 
expression, and cancer colony formation in direct co-culture.  
Conclusion: These results provide insight into the mechanistic role of miR-29 in PDAC 
stroma and its potential use as an anti-stromal/angiogenic therapeutic agent. 
